Back to Newsroom

GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute

LOUISVILLE, CO–(Marketwired – April 22, 2015) – GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination with radiation therapy in patients with chordoma is open for enrollment at the National Cancer Institute (NCI). Christopher Heery, M.D., Head of the Clinical Trials Group at the NCI Laboratory of Tumor Immunology and Biology, is the principal investigator for the study. The Company believes that the GI-6301 Tarmogen®, exclusively licensed to Celgene Corporation, has demonstrated promising initial results in chordoma patients evaluated in a recent Phase 1 study.

Click here to read more